Login to Your Account



Zai Lab returns China rights for olmutinib to Hanmi

By David Ho
Staff Writer

Wednesday, April 11, 2018

HONG KONG – China's Zai Lab Ltd. has returned the exclusive sales license of lung cancer drug Olita Tab (olmutinib) to its developer, South Korea's Hanmi Pharmaceutical Co. Ltd., a move Zai attributed to reprioritization, though Olita Tab has run into problems in clinical studies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription